About

Fonterra is a global dairy nutrition company owned by 10,000 farmers and their families. Read about our company and about our farmers and markets.

explore this section

Investors

Are you an investor with Fonterra? Read about our current performance with our financial results, or find information on our dividend programme.

explore this section

Careers

Read about life at Fonterra and explore our current vacancies and future career opportunities.

explore this section

Media Releases

24-hour media line : +64 21 507 072
Email: communications@fonterra.com

November 29, 2019

2019 Sustainability Report shows Fonterra picking up the pace

Co-firing biomass to reduce coal, lifting the number of New Zealand products with Health Star ratings and launching an emissions profile for every farm headline Fonterra’s 2019 Sustainability Report.

November 15, 2019

Fonterra announces resignation of Deborah Capill - Managing Director, People & Culture

Today Fonterra announces that Deborah Capill, Managing Director – People & Culture has resigned. Deborah is set to leave the Co-operative in February 2020 to pursue a change in career.

September 25, 2019

Fonterra achieves $1 billion available for debt reduction

Fonterra today agreed the sale of its 50% share of DFE Pharma for $633 million (NZD). The cash from this sale, along with proceeds from our other asset sales across the year – which includes the significant contribution from Tip Top – will give us over $1 billion available for debt reduction.

September 17, 2019

Fonterra confirms annual results reporting date

Fonterra advises the new date for reporting its audited financial results for the financial year ended 31 July 2019 (FY19) will be 26 September 2019.

August 12, 2019

Fonterra provides update on earnings, dividend, and one-off accounting adjustments

Fonterra Co-operative Group Limited today reconfirmed its underlying earnings guidance for the 2019 financial year that ended on 31 July 2019 (FY19), announced a final decision on its full-year dividend for FY19, and provided further information on some significant adverse one-off items.